TICKERNERD
Menu
RCELRCELHealthcare · Medical Devices

RCEL Stock Forecast: AVITA Medical, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$9.88
+0.20% on the day

The 3 Wall Street analysts covering AVITA Medical, Inc. hold a median 12-month price target of $12 — +21.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$305.6M
Ticker Nerd rank
66 / 100
Median analyst target
$12
Analysts covering
3
Revenue$21.7M+17.8% y/y
Operating income−$6.9M
Net income−$7.7M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.7%
1M
+20.5%
YTD
+186.4%
1Y
+125.6%
From 52W high
−11.8%
From 52W low
+202.1%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RCEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AVITA Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Revisions
87
Momentum
72
Growth
62
Size
62
Value
42
Quality
40
Issuance
14
Volatility
13

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RCEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RCEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26RCELHigh $14Median $12Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $11Median $12High $14

The green dot is the last close — the median target sits +21.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 Aug 2026Lake StreetMaintainsBuy$8.00 → $12
19 Aug 2026BTIGMaintainsBuy$7.00 → $11
19 Aug 2026BTIGMaintainsBuy—
19 Aug 2026TD CowenMaintainsBuy$12 → $14
19 Aug 2026TD CowenMaintainsBuy—
7 Aug 2026BTIGUpgradeBuy—
7 Aug 2026BTIGUpgradeBuy$7.00
15 May 2026Lake StreetUpgradeBuy$3.50 → $6.00
15 May 2026Lake StreetUpgradeBuy—
9 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
5 Mar 2026Northland Capital MarketsInitiatesOutperform—
17 Feb 2026D. Boral CapitalMaintainsBuy—
26 Jan 2026D. Boral CapitalMaintainsBuy—
16 Jan 2026Lake StreetMaintainsHold—
15 Jan 2026D. Boral CapitalMaintainsBuy—
20 Nov 2025BTIGUpgradeNeutral—
7 Nov 2025D. Boral CapitalMaintainsBuy—
17 Oct 2025D. Boral CapitalMaintainsBuy—
17 Oct 2025Lake StreetDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCEL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RCEL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, AVITA Medical, Inc. returned +125.6% against +17.5% for the S&P 500, dividends included.

RCEL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26RCELS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RCEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

AVITA Medical, Inc. (RCEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.7×

Cheaper than 90% of US stocks

Price / sales
4.0×

Cheaper than 30% of US stocks

Price / book
−10.9×

Cheaper than 98% of US stocks

EV / EBITDA
−10.5×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
17.8%

Higher than 66% of US stocks

Earnings growth (YoY)
17.8%

Higher than 56% of US stocks

Gross margin
81.9%

Higher than 92% of US stocks

Operating margin
−31.6%

Higher than 19% of US stocks

Net margin
−57.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
291.8%

Higher than 99% of US stocks

Return on assets
−41.6%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AVITA Medical, Inc. (RCEL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AVITA Medical, Inc. has a market value of $305.6M and an enterprise value of $342.9M.

  • Revenue in the twelve months to 30 June 2026: $75.6M. The latest quarter grew 17.8% year on year.

  • Net income over the same four quarters: −$43.1M, a −57.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.44.

  • Free cash flow in the twelve months to 30 June 2026: −$25.3M.

  • Shares outstanding: 30.9M.

  • Trailing P/E: −5.7×; forward P/E: −23.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • AVITA Medical, Inc. employs 226 people — $335K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

RCEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
RCELAVITA Medical, Inc.$305.6M
66
TMCITreace Medical Concepts, Inc.$287.4M
56
CATXPerspective Therapeutics, Inc.$320.1M
30
TLSITriSalus Life Sciences, Inc.$279.0M
34
CVCapsoVision, Inc.$328.9M
20
MOBIMobia Medical, Inc.$331.2M
2
VMDViemed Healthcare, Inc.$334.2M
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AVITA Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RCEL news & analysis

AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

AVITA Medical announced that its senior management will participate in two upcoming investor conferences: the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, 2026 in New York, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, with investor meetings featuring CEO Cary Vance and CFO David O'Toole.

Why it matters — RCEL watchers would care because the company's leadership will present and hold investor meetings at two major industry conferences, offering exposure to institutional investors.

All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy

Zacks Investment Research · 31 Aug 2026positive

Zacks Investment Research upgraded Avita Medical (RCEL) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The upgrade reflects a more favorable view of RCEL's near-term outlook.

Why it matters — A Zacks upgrade to a Buy rank signals increased analyst confidence in RCEL's earnings trajectory, which RCEL watchers watch closely as an indicator of expected share-price movement.

Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research published an analysis examining whether Avita Medical Inc. (RCEL) qualifies as a strong momentum stock for investors. The piece poses the question of whether the company has what it takes to become a top momentum pick.

Why it matters — A momentum-focused assessment can influence how investors perceive RCEL's recent price and earnings trends, making it relevant for those tracking the stock's market position.

AVITA Medical: Favorable Reimbursements For Skin Wound Care

Seeking Alpha · 24 Aug 2026positive

AVITA Medical's reimbursement is becoming more predictable, removing a key adoption barrier for its skin wound care products. The RECELL GO international rollout and PermeaDerm's positive clinical economics are broadening the company's long-term potential, while management expects to reach its cash flow breakeven target by Q4 2026.

Why it matters — For RCEL watchers, more predictable reimbursement and an on-track cash flow breakeven target could reduce a key adoption barrier and help derisk the company's outlook.

Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft

MarketBeat · 19 Aug 2026positive

Avita Medical presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft. The headline reports a 70% cost reduction with PermeaDerm versus allograft.

Why it matters — The study results highlight a potential cost advantage of PermeaDerm over cadaveric allograft, which could be relevant to the company's wound coverage product.

FAQ

Frequently asked questions about RCEL stock

What is the RCEL stock price forecast for 2026-2027?

The 3 Wall Street analysts covering AVITA Medical, Inc. have a median 12-month price target of $12, with estimates ranging from $11 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RCEL stock a buy right now?

Of the 3 analysts covering AVITA Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AVITA Medical, Inc. 66 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RCEL?

As at 12 Sept 2026, AVITA Medical, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will RCEL stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +21.1% from the last close, and Ticker Nerd's factor model ranks AVITA Medical, Inc. 66 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RCEL stock forecast for 2030?

No analyst covering AVITA Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $14 over the next 12 months.

How has RCEL stock performed over the past year?

AVITA Medical, Inc. returned +125.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AVITA Medical, Inc. do?

AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing.

What is the latest news on RCEL?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference". AVITA Medical announced that its senior management will participate in two upcoming investor conferences: the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, 2026 in New York, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, with investor meetings featuring CEO Cary Vance and CFO David O'Toole.

Company

About AVITA Medical, Inc.

AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing. Its flagship RECELL System uses a patient’s own skin cells to create a spray-on cell suspension at the point of care for the treatment of thermal burn wounds, full-thickness skin defects, and stable depigmented vitiligo lesions. The company also markets PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix, supporting surgeons and clinicians in burn care, trauma care, and reconstructive procedures. AVITA Medical serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, AVITA Medical specializes in technologies designed to improve wound coverage and support clinical recovery in acute care settings.

CEO Mr. Cary G. Vance · 226 employees · United States · https://avitamedical.com